A nonprofit group called the Medicines Patent Pool has had licensing rights to the drug for the last five years. The deal was criticized for being too restrictive, as high-income countries were denied access to the drug, according to STAT.
Since Kaltera has shown to be somewhat effective in treating COVID-19, AbbVie said it would dedicate the intellectual property rights for the drug to the public.
“The big win here may be for people for HIV. Access to [Kaltera] has been a battle for years,” Ellen ‘t Hoen, a senior researcher in the global health unit at the University of Groningen in the Netherlands, told STAT.
Read the full article here.
More articles on pharmacy:
CVS Health recruiting 50,000 workers amid COVID-19 pandemic
69 experimental COVID-19 drugs, treatments identified
Physicians found hoarding experimental COVID-19 treatments for relatives, report says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.